BioCentury
ARTICLE | Preclinical News

New protein complex sensitizes cancers to PARP inhibitors

April 17, 2018 4:43 PM UTC

Researchers at University of Copenhagen and colleagues used a network-based proteomics approach to identify shieldin, a protein complex that sensitizes BRCA1-deficient cancers to PARP inhibitors, suggesting that shieldin component levels could guide precision medicine strategies.

In a paper published in Cell, the team used a biotin labeling- and mass spectrometry-based method to generate spatially resolved network maps of DNA repair proteins involved in DNA damage response pathways...